Evidence map›Paper›PMID 32616158›Full record

Trial reportJournal of the American College of Cardiology2020

Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults.

Zhen Zhou, Richard Ofori-Asenso, Andrea J Curtis, Monique Breslin, Rory Wolfe, John J McNeil, Anne M Murray, Michael E Ernst, Christopher M Reid, Jessica E Lockery and 3 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American College of Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Effects of statins on kidney function in older adults.Journal of the American Geriatrics Society · 2025
    Trial
  3. Trial
  4. Low-Density-Lipoprotein Cholesterol and Mortality Outcomes Among Healthy Older Adults: A Post Hoc Analysis of ASPREE Trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024
    Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Zhen ZhouMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia. Electronic address: zhen.zhou@utas.edu.au.
Richard Ofori-AsensoDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Copenhagen Centre for Regulatory Science, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Andrea J CurtisDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Monique BreslinMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Rory WolfeDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
John J McNeilDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Anne M MurrayBerman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Division of Geriatrics, Department of Medicine, Hennepin HealthCare, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota.
Michael E ErnstDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa; Department of Family Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Christopher M ReidDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; School of Public Health, Curtin University, Perth, Western Australia, Australia.
Jessica E LockeryDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Robyn L WoodsDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Andrew M TonkinDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Mark R NelsonMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Monash University · AUUniversity of Tasmania · AUCurtin University · AUHennepin Healthcare Research Institute · USUniversity of Iowa · US

Funding

ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
Main Administrative CoreU19AG062682 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI CHAN, ANDREW T, MCNEIL, JOHN JAMES · 2019 to 2023
$42.9M
Research Education CoreP30AG024824 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Lona Mody, RAYMOND L YUNG · 2004 to 2026
$29.2M
NIA NIH HHS P30 AG024824NIA NIH HHS U01 AG029824NIA NIH HHS U19 AG062682
6 · The paper itself

Abstract

backgroundThere is clinical uncertainty regarding the benefits and harms of prescribing statins in healthy subjects ≥70 years of age.

objectivesThe aim of this study was to examine the association among statins, dementia-free and disability-free survival, and cardiovascular disease (CVD) among healthy older adults using data from the ASPREE (Aspirin in Reducing Events in the Elderly) trial.

methodsASPREE was a randomized trial of 19,114 community-dwelling persons in Australia and the United States ≥65 years of age and free of documented CVD, dementia, and disability. Data were collected for those ≥70 years of age, and participants who took statins at baseline were compared with those who did not using Cox proportional hazards regression with inverse probability weighting. The primary outcome, referred to as "disability-free survival," was a composite of all-cause mortality, dementia, or persistent physical disability. Other outcomes included the individual components of the composite outcome, major adverse cardiovascular events, fatal CVD, myocardial infarction, and stroke.

resultsOf the 18,096 included participants (median age 74.2 years, 56.0% women), 5,629 took statins at baseline. Over a median follow-up period of 4.7 years, baseline statin use was not associated with disability-free survival or with the risk for all-cause mortality or dementia. However, it was associated with lower risks for physical disability and all cardiovascular outcomes.

conclusionsAmong healthy community-dwelling adults ≥70 years of age, statin use may be beneficial for preventing physical disability and CVD but not beneficial for prolonging disability-free survival or avoiding death or dementia. Future clinical trials are needed to confirm these findings.

Indexed as

AgedAustraliaCardiovascular DiseasesDisability EvaluationDisease-Free SurvivalDouble-Blind MethodFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleSurvival RateUnited StatesHydroxymethylglutaryl-CoA Reductase Inhibitorsagedcardiovascular diseaseshydroxymethylglutaryl-CoA reductase inhibitorsprimary preventionsurvival

Identifiers

PMID32616158
PMCPMC7967891
OpenAlexW3037545403

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.